Cytek Biosciences (CTKB) Stock Price, News & Analysis

Company Overview

Cytek Biosciences is a life sciences tools company specializing in high-parameter spectral flow cytometry systems and accompanying reagents. The company develops, manufactures and markets instruments designed to enable researchers and clinicians to analyze complex cellular populations with enhanced sensitivity and resolution. Its solutions support workflows in immunology, oncology, cell therapy and other applications requiring multi-color analysis of individual cells.

Founded in 1998 as a research division focused on next-generation cytometry, Cytek Biosciences became an independent entity in the mid-2010s. Headquartered in Fremont, California, the company has expanded its global footprint with offices and technical support teams in Europe and the Asia-Pacific region. Over the years, Cytek has worked closely with leading academic institutions, biotechnology firms and pharmaceutical companies to advance single-cell analysis and accelerate drug discovery.

Key products include the Aurora and Northern Lights spectral flow cytometers, which leverage proprietary optics and fluidics to capture a broader spectrum of fluorescence signals. Complementary reagent kits and the SpectroFlo software platform enable users to design high-dimensional panels, automate data acquisition and perform sophisticated analysis. Cytek also offers customer training, instrument maintenance and assay development services to ensure optimal performance and reproducibility.

The company is led by Chief Executive Officer Luxin Ding, supported by a management team with deep expertise in cytometry, engineering and life sciences. Under this leadership, Cytek Biosciences continues to invest in research and development, expand its product portfolio and forge strategic partnerships aimed at meeting the evolving needs of the global cell analysis market.

Key Stats

• Today's Range: $3.59 to $3.82
• 50-Day Range: $2.42 to $3.86
• 52-Week Range: $2.37 to $7.63
• Volume: 776,901 shs
• Average Volume: 824,273 shs
• Market Capitalization: $476.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.60
• Consensus Rating: Hold

Cytek Biosciences Stock Analysis - MarketRank™

Cytek Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 360th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cytek Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cytek Biosciences has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.44% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Cytek Biosciences has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytek Biosciences does not currently pay a dividend.

Dividend Growth

Cytek Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.44% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Cytek Biosciences has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Cytek Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cytek Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTKB Stock Analysis - Frequently Asked Questions

How have CTKB shares performed this year?

Cytek Biosciences' stock was trading at $6.49 at the beginning of 2025. Since then, CTKB stock has decreased by 42.1% and is now trading at $3.76.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its earnings results on Thursday, May, 8th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $41.46 million for the quarter, compared to analyst estimates of $43.18 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 2.90% and a negative net margin of 5.71%.
Read the conference call transcript.

How will Cytek Biosciences' stock buyback program work?

Cytek Biosciences' Board of Directors authorized a share repurchase plan on Monday, December 30th 2024, which permits the company to buy back $50,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board believes its shares are undervalued.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytek Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:CTKB
• CIK: 1831915
• Web: www.cytekdev.com
• Phone: 877-922-9835
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.60
• High Stock Price Target: $8.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +48.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.02 million
• Net Margins: -5.71%
• Pretax Margin: -4.05%
• Return on Equity: -2.90%
• Return on Assets: -2.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.62
• Quick Ratio: 4.95

Sales & Book Value

• Annual Sales: $200.45 million
• Price / Sales: 2.38
• Cash Flow: $0.03 per share
• Price / Cash Flow: 108.35
• Book Value: $3.07 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 126,660,000
• Free Float: 113,575,000
• Market Cap: $476.24 million
• Optionable: Optionable
• Beta: 1.33